Inflammatory Skin Diseases

  1. Panel AAJADG, Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, Frazier WT, Greenhawt M, Huynh J, Kim E, LeBovidge J, Lind ML, Lio P, Martin SA, O’Brien M, Ong PY, Silverberg JI, Spergel JM, Wang J, Wheeler KE, Guyatt GH, Patient Groups: Global Parents for Eczema R, Capozza K, National Eczema A, Begolka WS, Evidence in Allergy G, Chu AWL, Zhao IX, Chen L, Oykhman P, Bakaa L, Parameters AAJTFoP, Golden D, Shaker M, Bernstein JA, Greenhawt M, Horner CC, Lieberman J, Stukus D, Rank MA, Wang J, Ellis A, Abrams E, Ledford D, Chu DK. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. Mar 2024;132(3):274-312.https://www.ncbi.nlm.nih.gov/pubmed/38108679
  2. Wan V, Habibi A, Abdi P, Mukovozov I, Asiniwasis RN, Maibach HI. Systematic scoping review on the barriers to access of biologics in moderate-to-severe adult atopic dermatitis. Australas J Dermatol. Mar 4 2024.https://www.ncbi.nlm.nih.gov/pubmed/38439194
  3. Zabihi H, Shojaei D, Seigel K, Al-Dehneem R, Piguet V, Croitoru DO. Evaluating the Clinical Utility of Sulfasalazine in the Treatment of Pyoderma Gangrenosum: A Systematic Review. J Cutan Med Surg. Mar 10 2024:12034754241238713.https://www.ncbi.nlm.nih.gov/pubmed/38462891
  4. Metko D, Mehta S, Piguet V. Cannabis Usage Among Patients With Hidradenitis Suppurativa: A Scoping Review. J Cutan Med Surg. Mar 10 2024:12034754241238719.https://www.ncbi.nlm.nih.gov/pubmed/38462895
  5. Riaz S, Emam S, Wang T, Gniadecki R. Negative impact of comorbidities on all-cause mortality of psoriasis patients is partially alleviated by biologic treatment: A real-world, case-control study. J Am Acad Dermatol. Feb 20 2024.https://www.ncbi.nlm.nih.gov/pubmed/38387852
  6. Ameen M, Alhusayen R, Brandi H, Bogelund M, Jensen HH, Reitzel SB, Thyssen JP. Patient Preferences in the Treatment of Moderate-to-severe Atopic Dermatitis. Acta Derm Venereol. Feb 21 2024;104:adv24339.https://www.ncbi.nlm.nih.gov/pubmed/38380974
  7. Gladman DD, Chandran V, Rosen CF, Rohekar S, Boyd T, Eder L, Rahman P, Dutz J, Chan J, Haydey RP, Barac S, Laliberte MC, Girard T, Fournier PA, Sutton M, Pereira D, Chim T, Coupal L, Choquette D. Residual Disease Activity In Canadian Patients With Psoriatic Arthritis (PsA) Treated With Advanced Therapies: Results From A Multi-Registry Analysis (UNISON-PsA). J Rheumatol. Feb 15 2024.https://www.ncbi.nlm.nih.gov/pubmed/38359937
  8. Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nunez JJ, Gomez-Escobar L, Perez-Herrera LC, Diaz Martinez JP, Brignardello-Petersen R, Sadeghirad B, Wong MM, Ceccacci R, Zhao IX, Basmaji J, MacDonald M, Chu X, Islam N, Gao Y, Izcovich A, Asiniwasis RN, Boguniewicz M, De Benedetto A, Capozza K, Chen L, Ellison K, Frazier WT, Greenhawt M, Huynh J, LeBovidge J, Lio PA, Martin SA, O’Brien M, Ong PY, Silverberg JI, Spergel JM, Smith Begolka W, Wang J, Wheeler KE, Gardner DD, Schneider L. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. The Journal of allergy and clinical immunology. Dec 2023;152(6):1493-1519.https://www.ncbi.nlm.nih.gov/pubmed/37678572
  9. Chu AWL, Wong MM, Rayner DG, Guyatt GH, Diaz Martinez JP, Ceccacci R, Zhao IX, McMullen E, Srivastava A, Wang J, Wen A, Wang FC, Brignardello-Petersen R, Izcovich A, Oykhman P, Wheeler KE, Wang J, Spergel JM, Singh JA, Silverberg JI, Ong PY, O’Brien M, Martin SA, Lio PA, Lind ML, LeBovidge J, Kim E, Huynh J, Greenhawt M, Gardner DD, Frazier WT, Ellison K, Chen L, Capozza K, De Benedetto A, Boguniewicz M, Smith Begolka W, Asiniwasis RN, Schneider LC, Chu DK. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. The Journal of allergy and clinical immunology. Dec 2023;152(6):1470-1492.https://www.ncbi.nlm.nih.gov/pubmed/37678577
  10. Panel AAJADG, Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, Frazier WT, Greenhawt M, Huynh J, Kim E, LeBovidge J, Lind ML, Lio P, Martin SA, O’Brien M, Ong PY, Silverberg JI, Spergel JM, Wang J, Wheeler KE, Guyatt GH, Patient Groups GPfER, Capozza K, National Eczema A, Begolka WS, Evidence in Allergy G, Chu AWL, Zhao IX, Chen L, Oykhman P, Bakaa L, Parameters AAJTFoP, Golden D, Shaker M, Bernstein JA, Greenhawt M, Horner CC, Lieberman J, Stukus D, Rank MA, Wang J, Ellis A, Abrams E, Ledford D, Chu DK. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. Dec 18 2023.https://www.ncbi.nlm.nih.gov/pubmed/38108679
  11. Brandling-Bennett HA, Arkin LM, Chiu YE, Hebert AA, Callen JP, Castelo-Soccio L, Co DO, Cordoro KM, Curran ML, Dalrymple AM, Flohr C, Gordon KB, Hanna D, Irvine AD, Kim S, Kirkorian AY, Lara-Corrales I, Lindstrom J, Paller AS, Reyes M, Begolka WS, Tom WL, Van Voorhees AS, Vleugels RA, Lee LW, Davies O, Siegfried EC. Executive summary: Consensus treatment guidelines for the use of methotrexate for inflammatory skin disease in pediatric patients. J Am Acad Dermatol. Feb 9 2024.https://www.ncbi.nlm.nih.gov/pubmed/38342248
  12. Deodhar A, Blauvelt A, Lebwohl M, Feely M, Kronbergs A, Eberhart N, Zhu D, Inman E, Grace E, Holzkaemper T, Rahman P, Marzo-Ortega H, Papp KA, Merola JF, Gottlieb AB, Schwartzman S. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials. Arthritis research & therapy. Feb 12 2024;26(1):49.https://www.ncbi.nlm.nih.gov/pubmed/38347650
  13. Machlab K, Yeung J, Gooderham M. Risankizumab in Adults with Psoriatic Arthritis. Skin Therapy Lett. Nov 2023;28(6):1-6.https://www.ncbi.nlm.nih.gov/pubmed/38015960
  14. Asiniwasis R, Merati N, Roesler J, Simpson EL, Aubry R, McMullen E, Fraess L, Choi UY, Hinther K, Chu DK, Jack C. ‘The Social and Home Environment: Impacts of Determinants of Health on Atopic Dermatitis, Pathways Towards Solutions, and Unique Considerations for Rural and Remote North American Indigenous Populations’. J Allergy Clin Immunol Pract. Nov 25 2023.https://www.ncbi.nlm.nih.gov/pubmed/38013155
  15. Schmid-Grendelmeier P, Gooderham MJ, Hartmann K, Konstantinou GN, Fellmann M, Koulias C, Clibborn C, Biswas P, Brunner PM. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies. Allergy. Nov 21 2023.https://www.ncbi.nlm.nih.gov/pubmed/37988255
  16. Papp KA, Lebwohl MG, Thaci D, Jaworski J, Kwiek B, Trefler J, Dudek A, Szepietowski JC, Reznichenko N, Narbutt J, Baran W, Kolinek J, Daniluk S, Bartnicka-Maslowska K, Reich A, Andrashko Y, Kim S, Bae Y, Jeon D, Jung J, Lee H, Pyo T, Ko W. Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study. BioDrugs. Nov 22 2023.https://www.ncbi.nlm.nih.gov/pubmed/37991693
  17. Zuberbier T, Abdul Latiff A, Aggelidis X, Augustin M, Balan RG, Bangert C, Beck L, Bieber T, Bernstein JA, Bertolin Colilla M, Berardi A, Bedbrook A, Bindslev-Jensen C, Bousquet J, de Bruin-Weller M, Bruscky D, Buyuktiryaki B, Canonica GW, Castro C, Chanturidze N, Chong-Neto HJ, Chu CY, Chularojanamontri L, Cork M, Criado RFJ, Barredo LC, Custovic A, Darsow U, Emurlai A, de Pablo A, Del Giacco S, Girolomoni G, Deleva Jovanova T, Deleuran M, Douladiris N, Duarte B, Dubakiene R, Eller E, Engel-Yeger B, Ensina LF, Filho NR, Flohr C, Fomina D, Francuzik W, Galimberti ML, Gimenez-Arnau AM, Godse K, Mortz CG, Gotua M, Hide M, Hoetzenecker W, Hunzelmann N, Irvine A, Jack C, Kanavarou I, Katoh N, Kinaciyan T, Kocaturk E, Kulthanan K, Lapeere H, Lau S, Machado Forti Nastri M, Makris M, Mansour E, Marsland A, Morelo Rocha Felix M, Moschione Castro AP, Nettis E, Nicolas JF, Nosbaum A, Odemyr M, Papapostolou N, Parisi CAS, Paudel S, Peter J, Pokharel P, Puig L, Quint T, Ramon GD, Regateiro F, Ricci G, Rosario C, Sackesen C, Schmid-Grendelmeier P, Serra-Baldrich E, Siemens K, Smith C, Staubach P, Stevanovic K, Su-Kucuk O, Sussman G, Tavecchio S, Teovska Mitrevska N, Thaci D, Toubi E, Traidl-Hoffmann C, Treudler R, Vadasz Z, van Hofman I, Ventura MT, Wang Z, Werfel T, Wollenberg A, Yang A, Weng Yew Y, Zhao Z, Zwiener R, Worm M. A concept for integrated care pathways for atopic dermatitis-A GA(2) LEN ADCARE initiative. Clin Transl Allergy. Sep 2023;13(9):e12299.https://www.ncbi.nlm.nih.gov/pubmed/37746794
  18. Mastacouris N, Tannenbaum R, Strunk A, Koptyev J, Aarts P, Alhusayen R, Bechara FG, Benhadou F, Bettoli V, Brassard A, Brown D, Choon SE, Coutts P, da Silva DLF, Daveluy S, Dellavalle RP, Del Marmol V, Emtestam L, Gebauer K, George R, Giamarellos-Bourboulis EJ, Goldfarb N, Hamzavi I, Hazen PG, Horvath B, Hsiao J, Ingram JR, Jemec GBE, Kirby JS, Lowes MA, Marzano AV, Matusiak L, Naik HB, Okun MM, Oon HH, Orenstein LAV, Paek SY, Pascual JC, Fernandez-Penas P, Resnik BI, Sayed CJ, Thorlacius L, van der Zee HH, van Straalen KR, Garg A. Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus Statement. JAMA Dermatol. Sep 27 2023.https://www.ncbi.nlm.nih.gov/pubmed/37755725
  19. Merola JF, Parish LC, Guenther L, Lynde C, Lacour JP, Staubach P, Cheng S, Paris M, Picard H, Deignan C, Jardon S, Chen M, Papp KA. Efficacy and Safety of Apremilast in Patients with Moderate-to-Severe Genital Psoriasis: Results from Discreet, a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial. J Am Acad Dermatol. Oct 16 2023.https://www.ncbi.nlm.nih.gov/pubmed/37852306
  20. Croitoru DO, Brooks SG, Nathanielsz N, Silverberg O, Nicolau I, Drucker AM, Silverberg M, Yeung J, Limacher JJ, Piguet V. Predictors of severity in paradoxical psoriasis from biologic therapies: A systematic review. J Am Acad Dermatol. Feb 2023;88(2):471-473.https://www.ncbi.nlm.nih.gov/pubmed/35718193
  21. Croitoru DO, Piguet V. Methylglyoxal Autoimmunity: A Hidden Link in HS and Associated Diseases? The Journal of investigative dermatology. Feb 2023;143(2):183-185.https://www.ncbi.nlm.nih.gov/pubmed/36681420
  22. Seigel K, Croitoru D, Lena ER, Dienes S, Alsukait S, Piguet V. Utility of Rituximab in the Treatment of Hidradenitis Suppurativa: A Systematic Review. J Cutan Med Surg. Mar-Apr 2023;27(2):176-177.https://www.ncbi.nlm.nih.gov/pubmed/36789521
  23. Croitoru DO, Piguet V. T Cells Remember SARS-CoV-2 in Rituximab-Treated Pemphigus Vulgaris. The Journal of investigative dermatology. Aug 2023;143(8):1340-1341.https://www.ncbi.nlm.nih.gov/pubmed/36959025
  24. O’Toole A, Gooderham M. Topical Roflumilast for Plaque Psoriasis. Skin Therapy Lett. Sep 2023;28(5):1-4.https://www.ncbi.nlm.nih.gov/pubmed/37734074
  25. Metelitsa A, Delorme I, O’Sullivan D, Zeinab R, Legault M, Gooderham M. A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology. Skin Therapy Lett. Sep 2023;28(5):5-11.https://www.ncbi.nlm.nih.gov/pubmed/37734108
  26. Warren RB, French LE, Blauvelt A, Langley RG, Egeberg A, Mrowietz U, Hunter HJA, Gooderham M, Soerensen P, Andres P, Sommer MOA, Carlsson A, Kjoller KD, Strober BE. Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, phase 2b trial (IASOS). J Am Acad Dermatol. Nov 9 2023.https://www.ncbi.nlm.nih.gov/pubmed/37951245
  27. Joly-Chevrier M, Gelinas A, Ghazal S, Moussa S, McCuaig CC, Piram M, Mereniuk A, Litvinov IV, Osman M, Pehr K, Netchiporouk E. Morphea, Eosinophilic Fasciitis and Cancer: A Scoping Review. Cancers. Sep 7 2023;15(18).https://www.ncbi.nlm.nih.gov/pubmed/37760419
  28. Tan J, Draelos ZD, Gooderham MJ, Alexis AF, Graber E, Keri J, Woolery-Lloyd HC, Harper JC, Cook-Bolden FE, Konda A, Tanghetti EA. Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of Acne. J Clin Aesthet Dermatol. Sep 2023;16(9):42-45.https://www.ncbi.nlm.nih.gov/pubmed/37720201
  29. Alexis AF, Silverberg JI, Rice ZP, Armstrong AW, Desai SR, Fonacier L, Kabashima K, Biswas P, Cella RR, Chan GL, Levenberg M. Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type. Ann Allergy Asthma Immunol. Nov 8 2023.https://www.ncbi.nlm.nih.gov/pubmed/37949351
  30. Gooderham MJ, Bissonnette R, Kalia S, Papp KA, Guenther LC, Gulliver WP, Ho V, Shear NH, Vender R, Gniadecki R, Prajapati VH, Turchin I, Langholff W, Parnell K, Simpson SD, Abbarin N, Lakhani O, Alhusayen R. Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Cutan Med Surg. Aug 11 2023:12034754231191509.https://www.ncbi.nlm.nih.gov/pubmed/37571829
  31. Gniadecki R, Osman M, Hennesey D, O’Keefe S, Thomsen SF, Iyer A. Architecture of skin inflammation in psoriasis revealed by spatial transcriptomics. Clin Immunol. Nov 2023;256:109771.https://www.ncbi.nlm.nih.gov/pubmed/37708923
  32. Osman M, Martins KJB, Wong KO, Vu K, Guigue A, Cohen Tervaert JW, Gniadecki R, Klarenbach SW. Incidence and prevalence, and medication use among adults living with dermatomyositis: an Alberta, Canada population-based cohort study. Scientific reports. Sep 30 2023;13(1):16444.https://www.ncbi.nlm.nih.gov/pubmed/37777591
  33. Ma Z, Johnson D, Gniadecki R, Ritchie B, Keeling S, Cohen Tervaert JW, Osman M. Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world single centre experience. Rheumatology (Oxford). Oct 5 2023.https://www.ncbi.nlm.nih.gov/pubmed/37796840
  34. Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova E, Gniadecki R, Hodak E, Jonak C, Klemke CD, Knobler R, Morrris S, Nicolay JP, Ortiz-Romero PL, Papadavid E, Pimpinelli N, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Vakeva L, Vermeer MH, Wehkamp U, Whittaker S, Willemze R, Trautinger F. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome – Update 2023. Eur J Cancer. Sep 18 2023;195:113343.https://www.ncbi.nlm.nih.gov/pubmed/37890355
  35. Graff P, Woerz D, Wilzopolski J, Voss A, Sarrazin J, Blimkie TM, Weiner J, 3rd, Kershaw O, Panwar P, Hackett T, Lau S, Bromme D, Beule D, Lee YA, Hancock REW, Gruber AD, Baumer W, Hedtrich S. Extracellular Matrix Remodeling in Atopic Dermatitis Harnesses the Onset of an Asthmatic Phenotype and Is a Potential Contributor to the Atopic March. The Journal of investigative dermatology. Oct 12 2023.https://www.ncbi.nlm.nih.gov/pubmed/37838332
  36. Nash P, Dutz JP, Peterson S, Patel BP, Eaton K, Shawi M, Zazzetti F, Wei JC. Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes. BMJ Open. Nov 8 2023;13(11):e062306.https://www.ncbi.nlm.nih.gov/pubmed/37940157
  37. Drucker AM, Lam M, Elsawi R, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN, Rochwerg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Schmitt J, Flohr C. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. The British journal of dermatology. Oct 13 2023.https://www.ncbi.nlm.nih.gov/pubmed/37831594
  38. Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Sidbury R. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. Nov 3 2023.https://www.ncbi.nlm.nih.gov/pubmed/37943240
  39. Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Sidbury R. Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. Nov 3 2023.https://www.ncbi.nlm.nih.gov/pubmed/37943241
  40. Renert-Yuval Y, Del Duca E, Arents B, Bissonnette R, Drucker AM, Flohr C, Guttman-Yassky E, Hijnen D, Kabashima K, Leshem YA, Paller AS, Silverberg JI, Simpson EL, Spuls P, Vestergaard C, Wollenberg A, Irvine AD, Thyssen JP. Treat-To-Target in Dermatology: A Scoping Review and International Eczema Council Survey on the Approach in Atopic-Dermatitis. J Eur Acad Dermatol Venereol. Sep 12 2023.https://www.ncbi.nlm.nih.gov/pubmed/37700595
  41. Liu L, Yang Q, Su MW, Zhou Y. Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001). JAAD Case Rep. Sep 2023;39:150-151.https://www.ncbi.nlm.nih.gov/pubmed/37693929
  42. Colaco K, Lee KA, Akhtari S, Winer R, Chandran V, Harvey P, Cook RJ, Piguet V, Gladman DD, Eder L. Derivation and Internal Validation of a Disease-specific Cardiovascular Risk Prediction Model for Patients with Psoriatic Arthritis and Psoriasis. Arthritis Rheumatol. Sep 11 2023.https://www.ncbi.nlm.nih.gov/pubmed/37691498
  43. Eyerich K, Gooderham MJ, Silvestre JF, Shumack SP, Mendes-Bastos P, Aoki V, Ortoncelli M, Silverberg JI, Teixeira HD, Chen SH, Calimlim BM, Takemoto S, Sancho C, Fritz B, Irvine AD. Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From a Multicountry Study. J Eur Acad Dermatol Venereol. Sep 5 2023.https://www.ncbi.nlm.nih.gov/pubmed/37669868
  44. Abdi P, Awad C, Anthony MR, Farkouh C, Kenny B, Maibach HI, Ogunyemi B. Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis. Arch Dermatol Res. Sep 4 2023.https://www.ncbi.nlm.nih.gov/pubmed/37665358
  45. Lee EY, Drucker AM. A detailed evaluation of dupilumab’s effect on sleep in adults with atopic dermatitis. The British journal of dermatology. Sep 2 2023.https://www.ncbi.nlm.nih.gov/pubmed/37658831
  46. Le AM, Gooderham M, Torres T. Abrocitinib for the treatment of atopic dermatitis. Immunotherapy. Sep 5 2023.https://www.ncbi.nlm.nih.gov/pubmed/37667972
  47. Yosipovitch G, Gooderham MJ, Stander S, Fonacier L, Szepietowski JC, Deleuran M, Girolomoni G, Su JC, Bushmakin AG, Cappelleri JC, Feeney C, Chan G, Thorpe AJ, Valdez H, Biswas P, Rojo R, DiBonaventura M, Myers DE. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2. Am J Clin Dermatol. Aug 25 2023.https://www.ncbi.nlm.nih.gov/pubmed/37624488
  48. Schachner LA, Alexis AF, Andriessen A, Berson D, Gold M, Goldberg DJ, Hu S, Keri J, Kircik L, Woolery-Lloyd H. Insights into acne and the skin barrier: Optimizing treatment regimens with ceramide-containing skincare. J Cosmet Dermatol. Aug 21 2023.https://www.ncbi.nlm.nih.gov/pubmed/37605504
  49. Zhu C, Gabrielli S, Khoury L, Osman M, Litvinov IV, Iannattone L, Lefrancois P, Netchiporouk E. Immunosenescence, Inflammaging and Dermatology: Insights and Opportunities. J Cutan Med Surg. Aug 18 2023:12034754231194009.https://www.ncbi.nlm.nih.gov/pubmed/37593990
  50. Beckett M, Tan J, Bonnardeaux E, Dutz J, Shojania K, To F, Obrzut A, Avina-Zubieta J, Huang K. Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients. Rheumatology (Oxford). Aug 16 2023.https://www.ncbi.nlm.nih.gov/pubmed/37584672
  51. Kircik L, Alexis AF, Andriessen A, Blattner C, Glick BP, Lynde CW, Gold LS. Psoriasis and Skin Barrier Dysfunction: The Role of Gentle Cleansers and Moisturizers in Treating Psoriasis. J Drugs Dermatol. Aug 1 2023;22(8):773-778.https://www.ncbi.nlm.nih.gov/pubmed/37556521
  52. Alexis AF, Woolery-Lloyd H, Andriessen A, Heath C, Han G. INDIVIDUAL ARTICLE: An Algorithm for the Management of Atopic Dermatitis in People With Skin of Color. J Drugs Dermatol. Aug 1 2023;22(8):SF386361s386363-SF386361s386310.https://www.ncbi.nlm.nih.gov/pubmed/37556528
  53. Hamm C, Ramsoondar N, McGillis M, Waugh M, Gooderham M, Giroux LL. The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients: A Retrospective Study. J Cutan Med Surg. Aug 9 2023:12034754231191458.https://www.ncbi.nlm.nih.gov/pubmed/37559454
  54. Eder L, Lee KA, Chandran V, Widdifield J, Drucker AM, Ritchlin C, Rosen CF, Cook RJ, Gladman DD. Derivation of a multivariable psoriatic arthritis risk estimation tool (PRESTO): a step towards prevention. Arthritis Rheumatol. Aug 9 2023.https://www.ncbi.nlm.nih.gov/pubmed/37555242
  55. Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M, Amin AZ, Liu J, Wu T, Azam T, Stakias V, Espaillat R, Sinvhal R, Soliman AM, Pang Y, Chen MM, Lebwohl MG. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. J Am Acad Dermatol. Aug 6 2023.https://www.ncbi.nlm.nih.gov/pubmed/37553030
  56. Miller AE, Zhang D, Shields BE, Borghesi A, Benincaso AR, Bernardo L, Ramien M, Lara-Corrales I, Kirkorian AY, Maguiness S, Drolet B. COVID-19 associated severe mucocutaneous blistering eruptions: A case series. Pediatr Dermatol. Aug 1 2023.https://www.ncbi.nlm.nih.gov/pubmed/37526023
  57. Guttman-Yassky E, Silverberg JI, Thaci D, Papp KA, Stander S, Beck LA, Kim BS, Hu X, Liu J, Calimlim BM, Vigna N, Crowley JT, Teixeira HD, Thyssen JP. Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase 2b, randomized, controlled trial. J Eur Acad Dermatol Venereol. Aug 1 2023.https://www.ncbi.nlm.nih.gov/pubmed/37528500
  58. Almuhanna N, Tobe SW, Alhusayen R. Risk of chronic kidney disease in hospitalized patients with hidradenitis suppurativa. Dermatology. Jul 24 2023.https://www.ncbi.nlm.nih.gov/pubmed/37487485
  59. Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, Pinter A, Reich A, Drogaris L, Wu T, Patel M, Soliman AM, Photowala H, Stakias V, Richter S, Papp KA. Comparison of risankizumab and apremilast for the treatment of adult patients with moderate plaque psoriasis eligible for systemic therapy: results from a randomised, open-label, assessor-blinded phase IV (IMMpulse) study. The British journal of dermatology. Jul 25 2023.https://www.ncbi.nlm.nih.gov/pubmed/37488811
  60. Gooderham MJ, Pink AE, Simpson EL, Silverberg JI, Guler E, Watkins M. Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice. Dermatol Ther (Heidelb). Jul 23 2023.https://www.ncbi.nlm.nih.gov/pubmed/37482564
  61. Hordinsky M, Hebert AA, Gooderham M, Kwon O, Murashkin N, Fang H, Harada K, Law E, Wajsbrot D, Takiya L, Zwillich SH, Wolk R, Tran H. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. Jul 17 2023.https://www.ncbi.nlm.nih.gov/pubmed/37455588
  62. Lam M, Spuls PI, Leshem YA, Gerbens LAA, Thomas KS, Arents B, Burton T, Flohr C, Drucker AM. Reporting of Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set Instruments in randomized clinical trials for systemic treatments in Atopic Dermatitis. The British journal of dermatology. Jul 12 2023.https://www.ncbi.nlm.nih.gov/pubmed/37434297
  63. Leducq S, Maruani A, Bodemer C, Biscardi S, Boccara O, Chinazzo MF, Mahe E, Plantin P, Fraitag S, Mazereeuw-Hautier J, Chiaverini C, Lemelle I, Bessis D, Bourrat E, Mallet S, Bonniaud B, Grall-Lerosey M, Martin L, Boralevi F, Piram M. Accurate diagnosis of acute hemorrhagic edema of infancy: a French multicenter observational study. Eur J Pediatr. Jul 11 2023.https://www.ncbi.nlm.nih.gov/pubmed/37432503
  64. Hardin J, Makadia R, Black S, Lara-Corrales I, Diaz LZ, Kirby JS, DeKlotz CMC. Characteristics and treatment pathways in pediatric and adult hidradenitis suppurativa: An examination using real world data. JAAD Int. Sep 2023;12:124-132.https://www.ncbi.nlm.nih.gov/pubmed/37409312
  65. Papp KA, Beecker J, Cooper C, Kirchhof MG, Pozniak AL, Rockstroh JK, Dutz JP, Gooderham MJ, Gniadecki R, Hong CH, Lynde CW, Maari C, Poulin Y, Vender RB, Walmsley SL. Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatol Ther (Heidelb). Jul 6 2023.https://www.ncbi.nlm.nih.gov/pubmed/37410208
  66. Mease P, Setty A, Papp K, Van den Bosch F, Tsuji S, Keiserman M, Carter K, Li Y, McCaskill R, McDearmon-Blondell E, Wung P, Tillett W. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study. Clin Exp Rheumatol. Jul 5 2023.https://www.ncbi.nlm.nih.gov/pubmed/37404160
  67. Scollan ME, Levin LE, Lucky AW, Hook KP, Peoples K, Bruckner AL, Feinstein JA, Pope E, McCuaig CC, Powell J, Eichenfield LF, Levy ML, Diaz L, Glick SA, Paller AS, Browning JC, Morel KD. Characterization of wound microbes in epidermolysis bullosa: A focus on Pseudomonas aeruginosa. Pediatr Dermatol. Jun 26 2023.https://www.ncbi.nlm.nih.gov/pubmed/37364926
  68. Starkey SY, Kashetsky N, Lam JM, Dutz J, Mukovozov IM. Chilblain-Like Lesions (CLL) Coinciding With the SARS-CoV-2 Pandemic in Children: A Systematic Review. J Cutan Med Surg. May-Jun 2023;27(3):277-284.https://www.ncbi.nlm.nih.gov/pubmed/37340564
  69. Kashetsky N, Turchin I. Utilization of Topical Ruxolitinib in Dermatology: A Review. Skin Therapy Lett. May 2023;28(3):8-13.https://www.ncbi.nlm.nih.gov/pubmed/37339609
  70. Bourkas AN, Lara-Corrales I. The role of nutrition, food allergies, and gut dysbiosis in immune-mediated inflammatory skin disease: a narrative review. Curr Opin Pediatr. Jun 13 2023.https://www.ncbi.nlm.nih.gov/pubmed/37335275
  71. Gupta AK, Talukder M, Carviel JL, Cooper EA, Piguet V. Combatting antifungal resistance: paradigm shift in the diagnosis and management of onychomycosis and dermatomycosis. J Eur Acad Dermatol Venereol. May 21 2023.https://www.ncbi.nlm.nih.gov/pubmed/37210652
  72. Stein Gold L, Thaci D, Thyssen JP, Gooderham M, Laquer V, Moore A, Natalie CR, Zhao F, Meskimen E, Elmaraghy H, Montmayeur S, Gallo G, Jimenez G, de Bruin-Weller M. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials. Am J Clin Dermatol. May 17 2023.https://www.ncbi.nlm.nih.gov/pubmed/37195407
  73. Mehta H, Jack C, Maari C, Saint-Cyr Proulx E, Bissonnette R, Ramirez-Valle F, Sarfati M. Oral prednisone regulates human skin T cells in delayed-type hypersensitivity reaction elicited by diphencyprone. Allergy. May 10 2023.https://www.ncbi.nlm.nih.gov/pubmed/37163280
  74. Strober B, Thaci D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. Immunotherapy. May 7 2023.https://www.ncbi.nlm.nih.gov/pubmed/37150956
  75. Cotton CH, Chen SX, Hussain SH, Lara-Corrales I, Zaenglein AL. Hidradenitis Suppurativa in Pediatric Patients. Pediatrics. Apr 27 2023.https://www.ncbi.nlm.nih.gov/pubmed/37102307
  76. Jann J, Gascon S, Drevelle O, Fradette J, Auclair-Gilbert M, Soucy G, Fortier LC, Faucheux N. Assessment of antibacterial properties and skin irritation potential of anodized aluminum impregnated with various quaternary ammonium. Biomater Adv. Apr 20 2023;150:213433.https://www.ncbi.nlm.nih.gov/pubmed/37104962
  77. Alsenaid A, Piguet V, Lansang P, Miller-Monthrope Y, Yeung J, Joseph M. Brodalumab-Induced Eczematous Reactions in Psoriasis Patients: Management With Switching to Risankizumab. J Cutan Med Surg. Apr 4 2023:12034754231167140.https://www.ncbi.nlm.nih.gov/pubmed/37014149
  78. Blauvelt A, Lebwohl M, Langley RG, Rowland K, Yang YW, Chan D, Miller M, You Y, Yu J, Thaҫi D, Foley P, Papp KA. Malignancy Rates Through 5 Years of Follow-up in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab: Pooled Results From the VOYAGE 1 and VOYAGE 2 Trials. J Am Acad Dermatol. Apr 3 2023.https://www.ncbi.nlm.nih.gov/pubmed/37019386
  79. Finstad A, Glockler-Lauf SD, Almuhanna N, Saskin R, Alhusayen R. Investigating the risk of malignancy in elderly patients with psoriasis: A population-based retrospective matched cohort study. J Am Acad Dermatol. May 2023;88(5):1129-1131.https://www.ncbi.nlm.nih.gov/pubmed/37069801
  80. McMullen EP, Syed SA, Espiritu KD, Grewal RS, Elder GA, Morita PP, Drucker AM. The Therapeutic Applications of Machine Learning in Atopic Dermatitis: A Scoping Review. J Cutan Med Surg. Apr 19 2023:12034754231168846.https://www.ncbi.nlm.nih.gov/pubmed/37073787
  81. Yeung J, Gooderham MJ, Hong HC, Lynde C, Prajapati VH, Lansang P, Turchin I, Wiseman M, Jack C, Ramien M, Purdy K, Grewal P. Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: A Canadian perspective. J Am Acad Dermatol. Apr 19 2023.https://www.ncbi.nlm.nih.gov/pubmed/37074241
  82. Kristensen LE, Soliman AM, Papp K, White D, Barcomb L, Lu W, Eldred A, Behrens F. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1. Rheumatology (Oxford). Feb 1 2023;62(2):629-637.https://pubmed.ncbi.nlm.nih.gov/35801915/
  83. Quaglino P, Scarisbrick J, Roccuzzo G, Abeldano A, Battistella M, McCormack C, Cowan R, Cozzio A, Cury-Martins J, Enz P, Geskin L, Guenova E, Kim YH, Knobler R, Litvinov IV, Miyagaki T, Molgo M, Nicolay J, Papadavid E, Pinter-Brown L, Pujol Vallverdu R, Querfeld C, Ortiz-Romero P, Stadler R, Vermeer MH, Bagot M, Hodak E. Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey. J Eur Acad Dermatol Venereol. Apr 2023;37(4):680-688.https://pubmed.ncbi.nlm.nih.gov/36606565/
  84. Gupta AK, Wang T, Polla Ravi S, Bamimore MA, Piguet V, Tosti A. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors. J Eur Acad Dermatol Venereol. Apr 2023;37(4):666-679.https://pubmed.ncbi.nlm.nih.gov/36478475/
  85. Eichenfield LF, Stein Gold L, Kircik LH, Werschler WP, Beer K, Draelos ZD, Tanghetti EA, Papp KA, Baldwin H, Lain E, Sadick N, Gooderham MJ, Konda A. Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study. Pediatr Dermatol. Mar 22 2023.https://pubmed.ncbi.nlm.nih.gov/36949579/
  86. Blauvelt A, Thaçi D, Papp KA, Ho V, Ghoreschi K, Kim BS, Miller M, Shen YK, You Y, Chan D, Yu J, Yang YW, Lebwohl MG, Gottlieb AB, Crowley J, Foley P. Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. The British journal of dermatology. Mar 22 2023.https://pubmed.ncbi.nlm.nih.gov/36944555/
  87. Croitoru DO, Piguet V. T Cells Remember SARS-CoV-2 in Rituximab-Treated Pemphigus Vulgaris. The Journal of investigative dermatology. Mar 21 2023.https://pubmed.ncbi.nlm.nih.gov/36959025/
  88. Abduelmula A, Gooderham MJ. Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion. J Cutan Med Surg. Mar 21 2023:12034754231163541.https://pubmed.ncbi.nlm.nih.gov/36942447/
  89. Papp KA, Melosky B, Sehdev S, Hotte SJ, Beecker JR, Kirchhof MG, Turchin I, Dutz JP, Gooderham MJ, Gniadecki R, Hong CH, Lambert J, Lynde CW, Prajapati VH, Vender RB. Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatol Ther (Heidelb). Mar 16 2023.https://pubmed.ncbi.nlm.nih.gov/36929121/
  90. Taylor S, Elbuluk N, Grimes P, Chien A, Hamzavi I, Alexis A, Gonzalez N, Weiss J, Kang S, Desai SR. Treatment recommendations for acne-associated hyperpigmentation: results of a Delphi consensus process and literature review. J Am Acad Dermatol. Mar 14 2023.https://pubmed.ncbi.nlm.nih.gov/36924935/
  91. Bowie AC, Tadrous M, Thiruchelvam D, Ivers NM, Mohan T, Tu K, Jaakkimainen L, Drucker AM. A comparison of family physician and dermatologist topical corticosteroid prescriptions: A population-based cross-sectional study. J Am Acad Dermatol. Mar 11 2023.https://pubmed.ncbi.nlm.nih.gov/36914480/
  92. Kimball AB, Prens EP, Passeron T, Maverakis E, Turchin I, Beeck S, Drogaris L, Geng Z, Zhan T, Messina I, Bechara FG. Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a Phase 2, randomized, placebo-controlled trial. Dermatol Ther (Heidelb). Mar 9 2023:1-13.https://pubmed.ncbi.nlm.nih.gov/36892753/
  93. Draelos ZD, Adam DN, Hong CH, Lebwohl MG, Lynde CW, Nahm WK, Papp KA, Pariser DM, Stein Gold L, Stewart D, Higham RC, Berk DR, Krupa D, Burnett P. Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial. The British journal of dermatology. Mar 9 2023.https://pubmed.ncbi.nlm.nih.gov/36890712/
  94. Bourkas AN, Pope E. Oral ivermectin treatment for an infant with crusted scabies. Cmaj. Mar 6 2023;195(9):E334.https://pubmed.ncbi.nlm.nih.gov/36878546/
  95. García-Romero MT, Tollefson M, Pope E, Brandling-Bennett HA, Paller AS, Keimig E, Arkin L, Wanat KA, Humphrey SR, Werth VP, Oza V, Jacobe H, Fett N, Cordoro KM, Medina-Vera I, Chiu YE. Development and validation of the morphea activity measure in patients with pediatric morphea. JAMA Dermatol. Mar 1 2023;159(3):299-307.https://pubmed.ncbi.nlm.nih.gov/36753150/
  96. Maleki-Yazdi KA, Heen AF, Zhao IX, Guyatt GH, Suzumura EA, Makhdami N, Chen L, Winders T, Wheeler KE, Wang J, Spergel J, Silverberg JI, Ong PY, O’Brien M, Martin SA, Lio PA, Lind ML, LeBovidge J, Kim E, Huynh J, Greenhawt M, Frazier WT, Ellison K, Capozza K, De Benedetto A, Boguniewicz M, Begolka WS, Asiniwasis RN, Schneider LC, Chu DK. Values and preferences of patients and caregivers regarding treatment of atopic dermatis (eczema): a systematic review. JAMA Dermatol. Mar 1 2023;159(3):320-330.https://pubmed.ncbi.nlm.nih.gov/36696136/
  97. Alavi A, Anand N, Yamanaka-Takaichi M, Piguet V, Simmers J, Machado M, Todd A, Kirby J. Evaluating the hidradenitis odor and drainage scale (HODS): A new validated potential instrument to assess odor and drainage in hidradenitis suppurativa-A cross-sectional study. JAAD Int. Mar 2023;10:75-76.https://pubmed.ncbi.nlm.nih.gov/36688101/
  98. Liy-Wong C, Tarango C, Pope E, Coates T, Bruckner AL, Feinstein JA, Schwieger-Briel A, Hubbard LD, Jane C, Torres-Pradilla M, Zmazek M, Lara-Corrales I. Consensus guidelines for diagnosis and management of anemia in epidermolysis bullosa. Orphanet J Rare Dis. Feb 23 2023;18(1):38.https://pubmed.ncbi.nlm.nih.gov/36823529/
  99. Kokolakis G, Warren RB, Strober B, Blauvelt A, Puig L, Morita A, Gooderham M, Körber A, Vanvoorden V, Wang M, de Cuyper D, Madden C, Nunez Gomez N, Lebwohl M. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. The British journal of dermatology. Feb 22 2023;188(3):330-340.https://pubmed.ncbi.nlm.nih.gov/36751950/
  100. Lebwohl MG, Hebert AA, Gooderham MJ. Roflumilast cream vs vehicle cream and chronic plaque psoriasis-reply. Jama. Feb 21 2023;329(7):595.https://pubmed.ncbi.nlm.nih.gov/36809324/
  101. Seigel K, Croitoru D, Lena ER, Dienes S, Alsukait S, Piguet V. Utility of rituximab in the treatment of hidradenitis suppurativa: a systematic review. J Cutan Med Surg. Feb 14 2023:12034754231154261.https://pubmed.ncbi.nlm.nih.gov/36789521/
  102. Wollenberg A, Kircik L, Simpson E, Brinker D, Katoh N, Rueda MJ, Issa M, Yang F, Feely M, Alexis A. Pooled analysis of baricitinib tolerability in patients with atopic dermatitis in relation to acne, headache, and gastrointestinal events from 8 clinical trials. Dermatitis. Feb 6 2023.https://pubmed.ncbi.nlm.nih.gov/36749121/
  103. Aaron M, Ramien ML, Powell J, McCuaig CC, Marcoux D, Piram M, Hatami A, Coulombe J. A retrospective single-centre case series of paediatric blistering severe cutaneous adverse reactions (SCARs): evaluation using new diagnostic classification confirms value of British Association of Dermatologists’ guidelines. Clin Exp Dermatol. Feb 3 2023.https://pubmed.ncbi.nlm.nih.gov/36733210/
  104. Gooderham M, Kircik L, Zirwas M, Lee M, Kempers S, Draelos Z, Ferris L, Jones T, Saint-Cyr Proulx E, Bissonnette R, Bhatia N, Koppel R, Guenthner S, Eads K, Welgus H, Merritt C, Elias M, Navale L, Higham R, Droege M, Berk D. The safety and efficacy of roflumilast cream 0.15% and 0.05% in patients with atopic dermatitis: randomized, double-blind, Phase 2 proof of concept study. J Drugs Dermatol. Feb 1 2023;22(2):139-147.https://pubmed.ncbi.nlm.nih.gov/36745371/
  105. Liu J, Cices A, Kaufman B, Sanabria-Gonzalez I, Alexis A. Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Foam in the Treatment of Psoriasis in Skin of Color. J Drugs Dermatol. Feb 1 2023;22(2):165-173.https://pubmed.ncbi.nlm.nih.gov/36745370/
  106. Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, Ferrucci S, Lima RG, Witte MM, Xu W, ElMaraghy H, Natalie CR, Pierce E, Blauvelt A. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). JAMA Dermatol. Feb 1 2023;159(2):182-191.https://pubmed.ncbi.nlm.nih.gov/36630140/
  107. Gooderham M, Papp KA, Lynde C, Delorme I, Beecker J, Albrecht L, Dei-Cas I, Brassard D, Prajapati VH, Vieira A, Rihakova L. Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry. Dermatol Ther (Heidelb). Feb 2023;13(2):535-553.https://pubmed.ncbi.nlm.nih.gov/36562944/
  108. Musters AH, Broderick C, Prieto-Merino D, Chiricozzi A, Damiani G, Peris K, Dhar S, De A, Freeman E, Arents BWM, Burton T, Bosma ALL, Chi CC, Fletcher G, Drucker AM, Kabashima K, de Monchy EF, Panda M, Wall DR, Vestergaard C, Mahé E, Bonzano L, Kattach L, Napolitano M, Ordoñez-Rubiano MF, Haufe E, Patruno C, Irvine AD, Spuls PI, Flohr C. The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry. J Eur Acad Dermatol Venereol. Feb 2023;37(2):365-381.https://pubmed.ncbi.nlm.nih.gov/36169355/
  109. Du AX, Ali Z, Ajgeiy KK, Dalager MG, Dam TN, Egeberg A, Nissen CVS, Skov L, Thomsen SF, Emam S, Gniadecki R. Machine learning model for predicting outcomes of biologic therapy in psoriasis. J Am Acad Dermatol. Jan 30 2023.https://pubmed.ncbi.nlm.nih.gov/36720368/
  110. Muntyanu A, Gabrielli S, Donovan J, Gooderham M, Guenther L, Hanna S, Lynde C, Prajapati VH, Wiseman M, Netchiporouk E. The burden of alopecia areata: A scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol. Jan 27 2023.https://pubmed.ncbi.nlm.nih.gov/36708097/
  111. Ong PY, Boguniewicz J, Chu DK. Skin Antiseptics for Atopic Dermatitis: Dissecting Facts From Fiction. J Allergy Clin Immunol Pract. Jan 23 2023.https://pubmed.ncbi.nlm.nih.gov/36702247/
  112. Zinter MS, Markovic D, Asaro LA, Nadkarni VM, McQuillen PS, Sinha P, Matthay MA, Jeschke MG, Agus MSD, Sapru A. Tight Glycemic Control, Inflammation, and the ICU: Evidence for Heterogeneous Treatment Effects in Two Randomized Controlled Trials. Am J Respir Crit Care Med. Jan 19 2023.https://pubmed.ncbi.nlm.nih.gov/36656551/
  113. Bourkas AN, Pope E, Mendoza-Londono R, Kamath BM, Lara-Corrales I. Early diagnosis of ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis syndrome: A case report. Pediatr Dermatol. Jan 19 2023.https://pubmed.ncbi.nlm.nih.gov/36655593/
  114. Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Davis DMR. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. Jan 11 2023.https://pubmed.ncbi.nlm.nih.gov/36641009/
  115. Blauvelt A, Pariser DM, Tyring S, Bagel J, Alexis AF, Soung J, Armstrong AW, Muscianisi E, Kianifard F, Steadman J, Sarkar RP, Garcet S, Krueger JG. Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study. J Dermatol Sci. Jan 9 2023.https://pubmed.ncbi.nlm.nih.gov/36690571/
  116. Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Davis DMR. Executive Summary: American Academy of Dermatology Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. Jan 6 2023.https://pubmed.ncbi.nlm.nih.gov/36623556/
  117. Williams JC, Alhusayen R, Guilbault S, Hills NK, Ingram JR, Kudlinski MV, Lowes MA, Marzano AV, Paul M, Villumsen B, Yannuzzi CA, Naik HB. Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 Registry. Dermatology. 2023;239(2):283-286.https://pubmed.ncbi.nlm.nih.gov/36566748/
  118. Loo WJ, Turchin I, Prajapati VH, Gooderham MJ, Grewal P, Hong CH, Sauder M, Vender RB, Maari C, Papp KA. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway. J Cutan Med Surg. Jan-Feb 2023;27(1_suppl):3s-24s.https://pubmed.ncbi.nlm.nih.gov/36519621/
  119. Papp KA, Gooderham M, Dei-Cas I, LopezTello A, Garcia-Rodriguez JC, Taveras CY, Rousselin AH, Lavieri A, Maiolino M, Quintero DGV, Rihakova L, Salibe M, Pertuz W. Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data. Dermatol Ther (Heidelb). Jan 2023;13(1):269-283.https://pubmed.ncbi.nlm.nih.gov/36496547/
  120. Voisin A, Al-Ali A, Abduelmula A, Gooderham MJ. Reasons for the Termination of Interleukin-17 Inhibitor Medications in the Treatment of Plaque Psoriasis: A Real-World Retrospective Study. J Cutan Med Surg. Jan-Feb 2023;27(1):67-69.https://pubmed.ncbi.nlm.nih.gov/36471620/
  121. Gulliver W, Gooderham MJ, Zhu B, Jossart C, Montmayeur S, Burge R, Reed C. Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program. Dermatol Ther (Heidelb). Jan 2023;13(1):235-244.https://pubmed.ncbi.nlm.nih.gov/36436161/
  122. Capozza K, Funk M, Hering M, Lang J, Merhand S, Manion R, Orevillo K, Picozza M, Proctor A, Schwennesen T, Begolka WS, Tullos K, Talent C, Tu M, Vastrup AS, Schwartz A. Patients’ and Caregivers’ Experiences With Atopic Dermatitis-Related Burden, Medical Care, and Treatments in 8 Countries. J Allergy Clin Immunol Pract. Jan 2023;11(1):264-273.e261.https://pubmed.ncbi.nlm.nih.gov/36332836/
  123. Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, Chih-Ho Hong H, Hendrickson B, Dilley D, Tenorio AR, Ladizinski B, Chu AD, Liu J, Irvine AD. Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies. The Journal of allergy and clinical immunology. Jan 2023;151(1):172-181.https://pubmed.ncbi.nlm.nih.gov/36195170/
  124. Yepes-Nuñez JJ, Guyatt GH, Gómez-Escobar LG, Pérez-Herrera LC, Chu AWL, Ceccaci R, Acosta-Madiedo AS, Wen A, Moreno-López S, MacDonald M, Barrios M, Chu X, Islam N, Gao Y, Wong MM, Couban R, Garcia E, Chapman E, Oykhman P, Chen L, Winders T, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, Frazier WT, Greenhawt M, Huynh J, Kim E, LeBovidge J, Lind ML, Lio P, Martin SA, O’Brien M, Ong PY, Silverberg JI, Spergel J, Wang J, Wheeler KE, Schneider L, Chu DK. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms. The Journal of allergy and clinical immunology. Jan 2023;151(1):147-158.https://pubmed.ncbi.nlm.nih.gov/36191689/
  125. Abduelmula A, Mufti A, Mistry J, Sachdeva M, Beecker J, Prajapati VH, Yeung J. Management of Alopecia Areata With Topical JAK Inhibitor Therapy: An Evidence-Based Review. J Cutan Med Surg. Jan-Feb 2023;27(1):73-75.https://pubmed.ncbi.nlm.nih.gov/36189927/
  126. Pavel AB, Del Duca E, Cheng J, Wu J, Ungar B, Estrada YD, Jack C, Maari C, Proulx É S, Ramirez-Valle F, Krueger JG, Bissonnette R, Guttman-Yassky E. Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases. Allergy. Jan 2023;78(1):178-191.https://pubmed.ncbi.nlm.nih.gov/36178084/
  127. Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. Jan 2023;88(1):40-51.https://pubmed.ncbi.nlm.nih.gov/36115523/
  128. Blauvelt A, Kircik L, Papp KA, Simpson EL, Silverberg JI, Kim BS, Kwatra SG, Kuligowski ME, Venturanza ME, Wei S, Szepietowski JC. Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. Jan 2023;37(1):137-146.https://pubmed.ncbi.nlm.nih.gov/36066323/
  129. Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. Jan 2023;88(1):29-39.https://pubmed.ncbi.nlm.nih.gov/35820547/
  130. Haberman RH, MacFarlane KA, Catron S, Samuels J, Blank RB, Toprover M, Uddin Z, Hu J, Castillo R, Gong C, Qian K, Piguet V, Tausk F, Yeung J, Neimann AL, Gulliver W, Thiele RG, Merola JF, Ogdie A, Rahman P, Chakravarty SD, Eder L, Ritchlin CT, Scher JU. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. Dec 23 2022;12(12):e063650.https://pubmed.ncbi.nlm.nih.gov/36564123/
  131. Jackson JM, Alexis A, Zirwas M, Taylor S. Unmet needs for patients with seborrheic dermatitis. J Am Acad Dermatol. Dec 17 2022.https://pubmed.ncbi.nlm.nih.gov/36538948/
  132. Jelousi S, Sharma D, Alexis A, Murase JE. The Impact of Global Health Disparities on Atopic Dermatitis in Displaced Populations: Narrowing the Health Equity Gap for Patients with Skin of Color. Dermatol Ther (Heidelb). Dec 2022;12(12):2679-2689.https://pubmed.ncbi.nlm.nih.gov/36261772/
  133. Ding J, Joseph M, Chawla S, Yau N, Khosa Z, Khawaja F, Khosa F. Disparities in psoriasis clinical trials: A cross-sectional analysis. J Am Acad Dermatol. Dec 2022;87(6):1386-1389.https://pubmed.ncbi.nlm.nih.gov/36113618/
  134. Reich K, Lio PA, Bissonnette R, Alexis AF, Lebwohl MG, Pink AE, Kabashima K, Boguniewicz M, Nowicki RJ, Valdez H, Zhang F, DiBonaventura M, Cameron MC, Clibborn C. Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis. J Allergy Clin Immunol Pract. Dec 2022;10(12):3228-3237.e3222.https://pubmed.ncbi.nlm.nih.gov/36108923/
  135. Eveillard LA, Quartier P, Ouldali N, Bader-Meunier B, Aeschlimann F, Abasq C, Ballot C, Bouric P, Desdoits A, Dumaine C, Galeotti C, Hentgen V, Lefevre-Utile A, Chausset A, Hubiche T, Kupfer-Bessaguet I, Leclerq-Mercier S, Mallet S, Melki I, Merlin E, Miquel J, Piram M, Talmud D, Garcelon N, Vinit C, Welfringer A, Bourrat E, Meinzer U. Association of atypical skin manifestations at the onset of systemic juvenile idiopathic arthritis with difficult-to-treat disease: A retrospective multicenter study. J Am Acad Dermatol. Dec 2022;87(6):1425-1428.https://pubmed.ncbi.nlm.nih.gov/35963289/
  136. Muntyanu A, Le M, Ridha Z, O’Brien E, Litvinov IV, Lefrançois P, Netchiporouk E. Novel role of long non-coding RNAs in autoimmune cutaneous disease. J Cell Commun Signal. Dec 2022;16(4):487-504.https://pubmed.ncbi.nlm.nih.gov/34346026/
  137. Alexis A, Woolery-Lloyd H, Andriessen A, Kang S, Rodriguez D, Callender V. Racial/Ethnic Variations in Acne: A Practical Algorithm for Treatment and Maintenance, Including Skincare Recommendations for Skin of Color Patients With Acne. J Drugs Dermatol. Nov 1 2022;21(11):s13223-s132214.https://pubmed.ncbi.nlm.nih.gov/36342741/
  138. Mahmood F, Nguyen A, Muntyanu A, Jfri A, McCuaig C, Chédeville G, Piram M, Netchiporouk E. Prevalence and Incidence of Localized Scleroderma: A Qualitative Systematic Review. J Cutan Med Surg. Nov-Dec 2022;26(6):632-633.https://pubmed.ncbi.nlm.nih.gov/36225142/
  139. Mahé E, Beauchet A, Hadj-Rabia S, Mazereeuw-Hautier J, Mallet S, Phan A, Severino-Freire M, Boralevi F, Aubert H, Barthélémy H, Girard C, Martin L, Piram M, Barbarot S, Balguerie X, Zitouni J, Phan C, Di Lernia V. Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists. Dermatol Ther. Nov 2022;35(11):e15828.https://pubmed.ncbi.nlm.nih.gov/36107157/